Bevacizumab in the treatment of HER2-negative breast cancer

Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown...

Descripción completa

Detalles Bibliográficos
Autor principal: Lorusso, Vito
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727886/
https://www.ncbi.nlm.nih.gov/pubmed/19707460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727886/
https://www.ncbi.nlm.nih.gov/pubmed/19707460

Ejemplares similares